Thomas Lion, MD, PhD

St. Anna Children's Cancer Research Institute, Austria

Disclosure(s): SymBio Pharmaceuticals Limited: Advisor/Consultant, Grant/Research Support

Poster(s):

• (P-103) Adenoviremia Clearance Following Treatment with Intravenous (IV) Brincidofovir (BCV) in Immunocompromised Patients is Associated with Positive Clinical Disease Response: Preliminary Outcomes from the ATHENA Phase IIa Study
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT